Creyon’s aptamers enable precise, tissue-specific targeting of drug payloads while avoiding the limitations of antibody delivery modalities. Aptamers are small, structured RNA-based binding molecules with high specificity, high affinity, and tunable pharmokinetics.
They are synthesized with clinically validated chemistry and are highly compatible with oligonucleotide payloads (e.g., small interfering RNA [siRNA], antisense oligonucleotide [ASO]) and lipid nanoparticles (LNPs). Compared to antibodies and antibody fragment delivery molecules, aptamers present a low immunogenicity risk.
Overcoming Antibody-Based Delivery Limitations with Aptamers
Aptamers are the solution and cell-specific delivery is the killer app. Aptamers offer very small, structured RNA-based binders, high specificity, affinity, and tunable pK, synthesized with clinically validated chemistry. Aptamers are highly compatible with oligonucleotides payloads (siRNA, ASO) and LNPs and offer a fast and cost-efficient discovery process.
Creyon’s proprietary aptamer platform achieves fast and cost-efficient in vivo validation in 6-12 months. Our 100% backbone modified aptamers are made from the same chemistry as other FDA approved oligonucleotides. Our synthesis ready library design enables a one-step transition from initial results to drug-like molecules.
Aptamers have significant advantages over antibody-based delivery modalities including self-administered subcutaneous delivery, higher tissue penetration due to smaller size, highly controlled and titratable dosing due to tunable pK, low immunogenicity risk, and simple, fast, low cost of goods sold with no cold chain requirements.
Aptamer-based delivery platform key attributes
Improved Tissue Targeting
Aptamers enable highly specific, receptor-mediated targeting with a smaller and more flexible molecular structure than antibodies. This allows for enhanced tissue and cellular access, improving delivery in tissues that are difficult to reach with antibody-based systems.
More Favorable Pharmacology
Unlike antibodies, aptamers offer tunable binding, predictable distribution, and controlled clearance. This enables more consistent exposure at the target site and greater control over dosing and duration of effect.
Reduced Immunogenicity Risk
Aptamers are non-protein, nucleic acid–based molecules that avoid many of the immune responses associated with antibody therapies. Their defined chemistry and lack of Fc-mediated activity help reduce immunogenicity and off-target safety concerns.
Efficient CMC
Aptamers are manufactured through well-established, scalable chemical synthesis rather than slow complex biologic production. This enables faster development timelines improved batch-to-batch consistency compared to antibody-based delivery systems.